Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous cancer with limited advances in frontline treatment.
• Genomic subtyping has improved understanding, but standard chemoimmunotherapy remains unchanged.
• High-throughput analysis offers potential for personalized treatment strategies through drug-gene interactions.

Purpose of the Study:

• To identify targetable somatic mutations in DLBCL associated with unfavorable outcomes.
• To characterize drug-gene interactions for these mutations.
• To identify patient subgroups eligible for precision medicine.

Main Methods:

• Systematic literature review to compile somatic mutations in DLBCL.
• Extraction of mutation data and assessment of associations with pathways, subtypes, and outcomes.
• Second review to identify studies characterizing drug-gene interactions for identified mutations.

Main Results:

• Twenty-two targetable mutations in ≥5% of DLBCL patients were linked to poor outcomes, identifying 31.7% of cases for targeted therapy.
• 256 studies characterized drug-gene interactions for these mutations through in vitro, in vivo, and clinical trial data.
• Informatics tools integrated review data to identify high-risk subgroups and drug-gene interactions.

Conclusions:

• A novel approach linked systematic reviews and informatics to identify high-risk DLBCL subgroups.
• DLBCL-specific drug-gene interactions were identified, paving the way for targeted therapies.
• This research highlights potential patient populations for precision medicine trials in DLBCL.